Navigation Links
Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
Date:3/31/2009

Inc., a private pharmaceutical company. In 2004, Narachi retired as an officer and Vice President and General Manager of Amgen's Anemia Business. Throughout his 20 years at Amgen, Narachi held various positions including: Product Development Team Leader for NEUPOGEN(R); Director of Clinical Operations in Thousand Oaks, Calif., and Cambridge, U.K.; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. He is also a director of AMAG Pharmaceuticals, Inc.

Mr. Narachi received B.S. and M.A. degrees in Molecular Genetics from the University of California at Davis. He also received an M.B.A. from the Anderson Graduate School of Management at University of California, Los Angeles.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
4. Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City
5. Oxygen Biotherapeutics, Inc. Establishes Warfighter Division
6. Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. MRSA study suggests strategy shift needed to develop effective therapeutics
9. Cell Therapeutics, Inc. (CTI) President Craig Philips to Present at Invest Northwest
10. MPM Capital Leads Investment in Proteon Therapeutics
11. Cell Therapeutics Reschedules Special Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... New York (PRWEB) July 28, 2014 According ... Mark Caller, principal owner of The Marcal Group ... Harel Media Group (HMG). A contract, as well a broad ... Medical Center’s website, as well as branding services and marketing. ... the work completed by HMG throughout the course of the ...
(Date:7/28/2014)... 28, 2014 TherapySites, the ... professionals, announced today its affiliation with the Illinois ... new relationship allows TherapySites to continue to extend their ... and promotional offers. , “There has been a fundamental ... With nearly 3 billion Internet users, it is ...
(Date:7/28/2014)... According to the Heartburn No More PDF review ... will help people get rid of acid reflux ... about heartburn and acid reflux. In addition, inside this book, ... risk factors for reflux disease. , Vkool informs in ... of symptoms of reflux disease naturally without medications. The book ...
(Date:7/28/2014)... 2014 Shore Points Capital announced today ... in Loftware, Inc., through a recapitalization of the Company ... the lead investor in Loftware for over nine years, ... leading international provider of enterprise level software solutions for ... great investment for us, and we are proud of ...
(Date:7/27/2014)... Hyaluronic Acid can hold 1,000 times ... to the power of Hyaluronic Serums. , "Hyaluronic acid ... of Sublime Beauty®. "But like collagen, it diminishes with ... improves skin moisture-retention and radiance." , Hyaluronic acid ... healthy and beautiful look. Key Ingredients in the serum ...
Breaking Medicine News(10 mins):Health News:Calko Medical Center Loses Website Twice over Non-Payment, According to Court Documents 2Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2
... ... is the ability to earn an income. It is this ability ... mortgage but also to plan and save for tomorrow,s college and retirement costs. ... percent of adults age 21 and over have taken measures to protect their ...
... , Gay Men,s Health Crisis Encourages ... , NEW YORK, Dec. 1 Today on World AIDS ... to continue helping diverse groups disproportionately affected by HIV and ... is announcing an innovative, interactive crystal methamphetamine resource, www.MyMethLife.org ...
... , LOS ANGELES, Dec. ... Clementines kicks off its 2009/2010 growing season with a fresh ... Joy Fawcett - an award-winning soccer player, coach and ... mentor moms on the sidelines and online. Combined with league ...
... functional MRI , TUESDAY, Dec. 1 (HealthDay News) ... a new study has found. , "What we have found ... lead exposure. Distinct areas of the brain are affected differently," ... Hospital Medical Center and a professor of radiology, pediatrics and ...
... to treatment worldwide provide reasons for hope , TUESDAY, Dec. ... still far from over, 2009 could prove to be a ... experts say. , In fact, earlier this month a United ... HIV globally has remained unchanged, at about 33 million, for ...
... intolerance (a condition less severe than gestational diabetes) exhibit ... after birth, according to a new study accepted for ... Endocrinology & Metabolism ( JCEM ). ... between gestational glucose intolerance and postpartum risk of metabolic ...
Cached Medicine News:Health News:Northwestern Mutual Survey Reveals That Most Americans Are Putting Their Income at Risk 2Health News:Northwestern Mutual Survey Reveals That Most Americans Are Putting Their Income at Risk 3Health News:Nation's Oldest AIDS Organization Launches Innovative Tool to Reach New Faces of HIV on World AIDS Day 2Health News:Nation's Oldest AIDS Organization Launches Innovative Tool to Reach New Faces of HIV on World AIDS Day 3Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 2Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 3Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 4Health News:Childhood Lead Exposure Causes Permanent Damage: Study 2Health News:A Good Year in the Fight Against AIDS 2Health News:A Good Year in the Fight Against AIDS 3Health News:A Good Year in the Fight Against AIDS 4Health News:Glucose intolerance in pregnancy associated with postpartum cardiovascular risk 2
(Date:7/25/2014)...  Acsis Inc., the market leader for supply ... recently posted an article, "Future of Running ... needs for companies, extended supply chain, and explains ... no longer work today.  The article explains how ... mobile technology, machine to machine (M2M) connectivity, and ...
(Date:7/25/2014)... According to a new market ... Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and ... and Forecast (Value and Volume), 2013 - 2019", the ... in 2012 and is expected to grow at a ... USD 32.24 billion in 2019. Browse the ...
(Date:7/25/2014)... DUBLIN , July 25, 2014 ... the "Global Ophthalmic Diagnostic Devices Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 About Ophthalmic Diagnostic Device ... device used to identify a defect or deficiency in ... patients with ophthalmic disorders such as presbyopia, cataracts, glaucoma, ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... Simpson Eldredge Hersh & Jardine, P.C., one of the nations, ... lawsuit in Ohio against DePuy Orthopaedics, Inc. on behalf of ... ASR XL Acetabular System hip replacement. On August ... Johnson (NYSE: JNJ ), announced a voluntary recall ...
... Sept. 28 Cobalis Corp. (Pink Sheets: ... Call to provide investors and shareholders with further details and ... and legal issues. Shareholders and investors MUST RSVP ... October 5, 2010 at 1:15pm Pacific Time. Interested parties may ...
Cached Medicine Technology:Class Action Lawsuit Filed Against DePuy Orthopaedics, Inc. 2Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010 2
... enable all those involved with healthcare decisions ... very latest evidence in their field of ... each year as the volume of evidence ... delivering the best single source available for ...
... concise yet complete eTextbook of standard ... disease. In addition to the Redi-Reference ... full desktop version is included at ... the electronic textbook, Redi-Reference provides periodic ...
ECG pocket is a handy reference for identifying common ECG findings....
... involved with healthcare decisions to keep up ... in their field of interest - a ... the volume of evidence increases. Cochrane Reviews ... single source available for continually updated evidence-based ...
Medicine Products: